ABVC Biopharma Announces Letter to Shareholders
FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (Nasdaq:…
FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (Nasdaq:…
FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (Nasdaq:…
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
– Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline…
– Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline…
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Axial Therapeutics Inc., a clinical-stage biopharmaceutical company…
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Axial Therapeutics Inc., a clinical-stage biopharmaceutical company…
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the…
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the…
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering…
DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering…
SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…